Israel - Ibrani - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

Israel - Ibrani - Ministry of Health

teva israel ltd - diltiazem hydrochloride - טבליה - diltiazem hydrochloride 30 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - diltiazem hydrochloride - טבליה - diltiazem hydrochloride 60 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

Israel - Ibrani - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Israel - Ibrani - Ministry of Health

teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 150 mg - atazanavir

Israel - Ibrani - Ministry of Health

teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 200 mg - atazanavir

Israel - Ibrani - Ministry of Health

teva israel ltd - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - darunavir - טבליות מצופות פילם - darunavir 800 mg - darunavir

Israel - Ibrani - Ministry of Health

teva israel ltd - valganciclovir as hydrochloride - טבליות מצופות פילם - valganciclovir as hydrochloride 450 mg - valganciclovir

Israel - Ibrani - Ministry of Health

teva pharmaceutical industries ltd, israel - fluvoxamine maleate - טבליה - fluvoxamine maleate 100 mg - fluvoxamine